NDAORALFOR SOLUTION, TABLET, FOR SOLUTION
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IDKIT:HP is an oral diagnostic kit containing citric acid anhydrous and 13C-labeled urea used to detect Helicobacter pylori infection via the urea breath test. This non-invasive diagnostic tool helps clinicians identify H. pylori colonization in patients with gastrointestinal symptoms. The product operates as a diagnostic agent rather than a therapeutic intervention.
LOE Approaching
Product is in late-stage commercial maturity with moderate competitive pressure (30/100), suggesting stable but not expanding team opportunities.
Mechanism of Action
Pharmacologic Class:
Helicobacter pylori Diagnostic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IDKIT:HP offers exposure to diagnostic product management and market access strategy in a mature, stable category. The LOE approaching phase presents career challenges, as team growth is unlikely and focus shifts toward cost management and generic defense rather than expansion.
Product ManagerField Sales Representative
Worked on IDKIT:HP at CooperSurgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.